Vaccine Formulation and Adjuvants are crucial components in the development of effective vaccines, enhancing their immunogenicity and efficacy. Vaccine formulation refers to the precise composition and preparation of vaccines, including the selection of antigens, adjuvants, stabilizers, and delivery systems. The primary goal of vaccine formulation is to stimulate a robust and long-lasting immune response against specific pathogens while ensuring safety and stability. This involves identifying and selecting antigens that are capable of eliciting an immune response and formulating them in a manner that enhances their stability and immunogenicity.
Adjuvants are substances added to vaccines to enhance the immune response to antigens. They work by activating and modulating the innate immune system, increasing antigen presentation and promoting the production of antibodies and memory cells. Common adjuvants include aluminum salts, oil-in-water emulsions, and saponins. The selection of adjuvants depends on various factors, including the type of antigen, the desired immune response, and safety considerations. Adjuvants can improve vaccine efficacy by reducing the amount of antigen required per dose, allowing for dose sparing and increasing the duration and magnitude of the immune response.
In addition to adjuvants, vaccine formulation may also include stabilizers, preservatives, and excipients to enhance vaccine stability, shelf-life, and safety. Stabilizers help protect vaccines from degradation during storage and transport, while preservatives prevent microbial growth and contamination. Excipients such as buffers and pH adjusters maintain the pH and osmolarity of the vaccine formulation, ensuring compatibility with the body's tissues.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia